Dr Andrew Paul

Senior Lecturer

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Andy holds a Senior Lectureship position in the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde and has 20 years experience of research and teaching across the Biomedical Science (BMS) and Pharmacy (MPharm) programmes related to application of protein biochemistry and molecular pharmacology, in the context of cellular signalling, to health and disease. Andy is a graduate of the University of Glasgow (BSc (Hons) Biochemistry; 1986-1990) and completed his second degree (PhD Biochemistry & Molecular Biology, 1990-1993) at the University of Glasgow in association with the Wellcome Foundation, Beckenham.

The work in Andy's research lab focusses on the role of the inhibitory kappaB kinases (IKKs) in the regulation of both Nuclear Factor kappaB (NFkappaB)-dependent and -independent transcription in mediating inflammatory-based responses relevant to infection, regulation of immunity, cardiovascular disease and cancer.

Publications

IL-1β stimulates a novel, IKKα -dependent, NIK -independent activation of non-canonical NFκB signalling: McIntosh Kathryn, Khalaf Yousif H, Craig Rachel, West Christopher, McCulloch Ashley, Waghmare Ajay, Lawson Christopher, Chan Edmond YW, MacKay Simon, Paul Andrew, Plevin Robin; Cellular Signalling Vol 107 (2023); https://doi.org/10.1016/j.cellsig.2023.110684
Determining the prognostic significance of IKKα in prostate cancer: Montes Melania, MacKenzie Lewis, McAllister Milly J, Roseweir Antonia, McCall Pamela, Hatziieremia Sophia, Underwood Mark A, Boyd Marie, Paul Andrew, Plevin Robin, MacKay Simon P, Edwards Joanne; The Prostate Vol 80, pp. 1188-1202 (2020); https://doi.org/10.1002/pros.24045
Compromised cardiovascular function in aged rats corresponds with increased expression and activity of calcium/calmodulin dependent protein kinase IIδ in aortic endothelium: McCluskey Claire, Mooney Laura, Paul Andrew, Currie Susan; Vascular pharmacology Vol 118-119 (2019); https://doi.org/10.1016/j.vph.2019.04.002
Inhibition of cytokine-mediated JNK signalling by purinergic P2Y11 receptors, a novel protective mechanism in endothelial cells: Ng Pei Y, McIntosh Kathryn A, Hargrave Gillian, Ho Ka H, Paul Andrew, Plevin Robin; Cellular Signalling Vol 51, pp. 59-71 (2018); https://doi.org/10.1016/j.cellsig.2018.07.016
CaMKIIδ interacts directly with IKKβ and modulates NF-kB signalling in adult cardiac fibroblasts: Martin Tamara P, McCluskey Claire, Cunningham Margaret R, Beattie James, Paul Andrew, Currie Susan; Cellular Signalling (2018); https://doi.org/10.1016/j.cellsig.2018.07.008
Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers: Anthony Nahoum G, Baiget Jessica, Berretta Giacomo, Boyd Marie, Breen David, Edwards Joanne, Gamble Carly, Gray Alexander I, Harvey Alan L, Hatziieremia Sophia, Ho Ka Ho, Huggan Judith K, Lang Stuart, Llona-Minguez Sabin, Luo Jia Lin, McIntosh Kathryn, Paul Andrew, Plevin Robin J, Robertson Murray N, Scott Rebecca, Suckling Colin J, Sutcliffe Oliver Brook, Young Louise C, MacKay Simon P; Journal of Medicinal Chemistry Vol 60, pp. 7043-7066 (2017); https://doi.org/10.1021/acs.jmedchem.7b00484

More publications

Professional activities

EMBO/FEBS Conference , Spain: Keynote/plenary speaker; 1/2008

More professional activities

Projects

Development of a first-in-class IKKalpha inhibitor for the treatment of castrate resistant p: MacKay, Simon (Principal Investigator) Halbert, Gavin (Co-investigator) Paul, Andrew (Co-investigator) Suckling, Colin (Co-investigator) Watson, David (Co-investigator); 01-Jan-2020 - 31-Jan-2024
Prevention of CXCL12 production in cells of the cardiovascular system by IKK alpha inhibition (BHF PhD Studentship): Plevin, Robin (Principal Investigator) Coats, Paul (Co-investigator) MacKay, Simon (Co-investigator) Paul, Andrew (Co-investigator); 01-Jan-2018 - 30-Jan-2022
A proof-of-concept study to establish a systematic approach for the discovery of allosteric sites in proteins: Anthony, Nahoum Guillaume Hsuan (Principal Investigator) Paul, Andrew (Co-investigator); 05-Jan-2015 - 31-Jan-2017
CXCL12 as a assay system for IKKapha inhibitor drugs: Plevin, Robin (Principal Investigator) Paul, Andrew (Co-investigator); 01-Jan-2015 - 31-Jan-2017
UNDERSTANDING THE EFFECTS OF CANCER RADIATION THERAPY ON ENDOTHELIAL CELL DYSFUNCTION- THE ROLE OF NUCLEAR FACTOR KAPPPA B: Plevin, Robin (Principal Investigator) Boyd, Marie (Co-investigator) Paul, Andrew (Co-investigator); Understanding the effects of cancer radiation therapy on endothelial cell dysfunction- the role of Nuclear factor kapppa B; 01-Jan-2013 - 30-Jan-2016
First-in-class drugs for CRPC: MacKay, Simon (Principal Investigator) Boyd, Marie (Co-investigator) Paul, Andrew (Co-investigator) Plevin, Robin (Co-investigator) Suckling, Colin (Co-investigator); 01-Jan-2013 - 30-Jan-2016

More projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing

Location Map

View University of Strathclyde in a larger map